Clinical trials: Ebola
Ebola Virus Disease
EBOla Post-Exposure Prophylaxis
EBO-PEP is a multicentre, multi-epidemic, phase III, comparative, controlled, randomised, strict superiority trial in two unblinded parallel arms.
- Trial name
- EBO-PEP (NCT06841614)
- Testing
- Ervebo, Inmazeb
- Where
- 4 sites in Democratic Republic of the Congo, Guinea and 2 more
- Volunteers
- 160 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Healthy
A Study to Assess the Safety and Immunogenicity of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants
The purpose of this study is to test the safety and immunogenicity of MVA-BN-Filo and Ad26.ZEBOV administered as heterologous prime-boost vaccine regimens in healthy adult participants.
- Trial name
- NCT02376400
- Testing
- MVA-BN-Filo, Ad26.ZEBOV
- Where
- 2 sites in Tanzania, Uganda
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Hemorrhagic Fever, Ebola
Evaluating the Safety of and Immune Response to a Human Parainfluenza Virus Type 3 Ebola Virus Vaccine (HPIV3-EbovZ GP) in Healthy Adults
The purpose of this study is to evaluate the safety, infectivity, and immunogenicity of the HPIV3-EbovZ GP Ebola vaccine candidate in healthy adults.
- Trial name
- NCT02564575
- Testing
- HPIV3-EbovZ GP Vaccine
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Ebola, Post-Acute Ebola Syndrome
Long-Term Neurologic and Neurocognitive Sequelae Following Pediatric Ebola Virus in Liberia
Background: Ebola virus disease (EVD) causes fever, vomiting, and diarrhea, and may cause internal bleeding. It is often fatal. EVD may also damage the brain and nervous system.
- Trial name
- NCT06811129
- Where
- Liberia
- Volunteers
- 328 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Ebola Virus Disease
A Study to Find Out if the New Ebola Vaccine is Safe and Stimulates Immunity That Might Protect Adults in Kilifi, Kenya.
Previous Ebola outbreaks have been limited to individual countries and contained by infection control activities. The current outbreak in West Africa is international, and air travel has resulted in a number of infected…
- Trial name
- NCT02296983
- Testing
- VSV-ZEBOV
- Where
- Kenya
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Ebola Sudan Virus Disease
A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Sudan Ebolavirus Vaccine in Healthy Adults
A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Sudan Ebolavirus Vaccine in Healthy Adults
- Trial name
- NCT06803342
- Testing
- cAd3-Sudan Vaccine
- Where
- 4 sites in United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Albert B. Sabin Vaccine Institute
Ebola Virus Disease
Safety and Immunogenicity of Ervebo® and Zabdeno® Booster Vaccines Against Ebola Virus Following Previous Vaccination with the Zabdeno/Mvabea® or Ervebo® Vaccine Schedules in DRC
The goal of this randomized controlled trial is to investigate whether individuals in DRC previously vaccinated with Zabdeno/Mvabea® or Ervebo® vaccine schedules against Ebola virus can be safely and adequately boosted with…
- Trial name
- EBO-BOOST (NCT06126822)
- Testing
- Zabdeno® booster, Ervebo® booster
- Where
- 2 sites in Democratic Republic of the Congo
- Volunteers
- 624 people, healthy volunteers welcome
- Sponsor
- Institute of Tropical Medicine, Belgium
Ebola Virus Disease
Addressing Medium- to Long-term EBOLA Associated Psychological Distress and Psychosocial Problems in Central Uganda
Screen participants attending 11 healthcare facilities in Mubende District for psychological distress using the locally validated Luganda or English version of the WHO- Self Report Questionnaire (SRQ-20).
- Trial name
- Ebola+D (NCT06093646)
- Testing
- Ebola+D intervention
- Where
- Uganda
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- MRC/UVRI and LSHTM Uganda Research Unit
Ebola Virus Disease
Clinical Study to Assess Efficacy and Safety of Amiodarone in Treating Patients With Ebola. Virus Disease (EVD) in Sierra Leone. EASE (EMERGENCY Amiodarone Study Against Ebola)
The purpose of this study is to evaluate the efficacy and safety of amiodarone in the treatment of patients afflicted with Ebola virus disease.
- Trial name
- EASE (NCT02307591)
- Testing
- Best Supportive Care, Best Supportive Care + Amiodarone
- Sponsor
- Emergency NGO Onlus
Ebola
GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus, and Safety in Male Ebola Survivors With Evidence of Ebola Virus Persistence in Semen
Background: Some people have Ebola virus in their body for months after they recover from Ebola virus disease. Some may have health problems from the virus while others are fine.
- Trial name
- NCT02818582
- Testing
- GS-5734
- Where
- 2 sites in Guinea, Liberia
- Volunteers
- 38 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)